News

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone for the Treatment of Major Depressive Disorders

SHIONOGI Announces the Start of the Wastewater Epidemiological Surveillance Service for the Novel Coronavirus in Japan

Notice Regarding an Exclusive license Agreement for a Sensitive Virus Detection Method of Viruses and Bacteria, Including Novel Coronavirus, between Hokkaido University and SHIONOGI

Th2 Chemokine TARC Kit "HISCL® TARC Assay Kit" is Approved for an Additional Indication as an Auxiliary for Assessment of COVID-19 Aggravation risk

Sign a MoU with World Anti-Doping Agency (WADA) to Prevent Misuse and Abuse of Medicines for Doping in Sports

SHIONOGI’s Greenhouse Gas Reduction Target Approved by “Science Based Targets (SBT) Initiative”

Notice Regarding the Signing of Basic Agreement of Business Partnership between SHIMADZU and SHIONOGI for Wastewater Surveillance for Viruses in the Field of Infectious Diseases, Including Novel Coronavirus

Shionogi Announces Corporate Reorganization and Personnel Reassignment

“Notice of Convocation of the 156th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 156th Annual General Meeting of Shareholders”

Shionogi Announces Novel Coronavirus Antigen test agent “LumiraDx SARS-CoV-2 Ag Test Strip” and diagnostic instrument launched in Japan

Transcript for FY2020 Financial Results

Financial Results, Supplement, and Presentation Material for FY2020

Judgment of the Complaint for the Rescission of Tax Reassessment by the Osaka Regional Taxation Bureau

Position and Policy Regarding Reduction of the Investment Unit

Shionogi and InveniAI initiate a research collaboration agreement aimed for AI-powered multi-target drug discovery collaboration

Notice of Revisions to Dividend Forecasts
(Divident Increase)

Shionogi Filed the Application for Marketing Approval of Th2 Chemokine TARC Kit "HISCL® TARC reagent" to Assist in Predicting the Exacerbation of COVID-19

Shionogi Participated in Japan Climate Initiative (JCI) and Supports JCI Statement

Shionogi Announces Agreement of Joint Sales with LumiraDx Japan Co., Ltd. for Novel Coronavirus Antigen test agent “LumiraDx SARS-CoV-2 Ag Test Strip” and diagnostic instrument in Japan

Wastewater surveillance to monitor COVID-19 starts in Osaka Prefecture

Shionogi Announces Personnel Reassignment

Notice Regarding the Status and Completion of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Notice regarding an initiation of Phase 2 clinical trial by BioAge aimed at treating older patients of COVID-19

Establishing an Automated System for the Analysis of SARS-CoV-2 in Wastewater

Shionogi Certified as Health and Productivity Management Organization 2021 for Fifth Consecutive Year

Shionogi has been Selected as one of the "Excellent Integrated Reports" by the GPIF's Domestic Equity Managers

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Shionogi Announces Corporate Reorganization and Personnel Reassignment

Dispatch employees to health centers in areas where new coronavirus infections have spread

Shionogi wins the “Environmental Report Excellence Award” for its Integrated Report/Environment Report at the “Environmental Communication Awards”

Shionogi has been recognized for “Leaderboard” in the “Supplier Engagement Leaderboard (Climate Change)”
by CDP

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Transcript for FY2020 3Q Financial Results

Financial Results for the Third Quarter of FY2020

Presentation Material for FY2020 Third Quarter Conference call

Shionogi and BioAge conclude a license agreement aimed at treating COVID-19

Shionogi Announces European Commission Approval of XOFLUZA® (Baloxavir Marboxil) for the Treatment and Post-Exposure Prophylaxis of Influenza Virus Infection

Shionogi Announces Approval of XOFLUZA® (Baloxavir Marboxil) in Taiwan for the Post-Exposure Prophylaxis of Influenza Virus Infection

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)